Pfizer anti-smoking drug has heart risks: US

Jun 16, 2011

US regulators said Thursday that the label on Pfizer's anti-smoking drug Chantix must be changed to warn of a slightly higher risk of heart problems in patients who already have cardiovascular disease.

The drug, also known as varenicline, was shown in a clinical trial of 700 smokers to be associated with an elevated risk of heart attack, angina, and in some patients when compared to a placebo.

"The prescribing information for this drug product will be strengthened to inform the public that use of varenicline may be associated with a small, increased risk of certain cardiovascular adverse events in patients who have cardiovascular disease," the said.

FDA has ordered the drug-maker to "conduct a large, combined analysis (meta-analysis) of randomized, placebo-controlled trials" and will update the public once that is complete.

Earlier this year, some 1,200 plaintiffs in the United States who claim Chantix causes depression or filed lawsuits against Pfizer.

The drug is approved in almost 90 countries around the world and used by some seven million Americans.

If Chantix is found to be dangerous it could be withdrawn from the US market, where sales have suffered since alleged links to depression and suicide mushroomed last year.

Explore further: New treatment approved for rare form of hemophilia

add to favorites email to friend print save as pdf

Related Stories

FDA adds heart warning to Pfizer anti-smoking pill

Jun 16, 2011

(AP) -- Federal health regulators are warning doctors and patients that Pfizer's anti-smoking drug Chantix may slightly increase the risk of heart attack and other cardiovascular problems.

FDA: New warning needed for Chantix

Feb 03, 2008

The U.S. Food and Drug Administration Friday called for increased awareness of the health risks of the smoking cessation drug varenicline.

FDA requires Chantix, Zyban to have warning

Jul 01, 2009

(AP) -- The Food and Drug Administration will require two smoking-cessation drugs, Chantix and Zyban, to carry the agency's strongest safety warning over side effects including depression and suicidal thoughts.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0